The current financial score of Emergent BioSolutions Inc is 8.13. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 234.30M, representing a year-over-year increase of 66.29%, while its net profit experienced a year-over-year increase of 1401.67%.
The current valuation score of Emergent BioSolutions Inc is 8.23. Its current P/E ratio is -50.07, which is -122.55% below the recent high of 11.29 and -39.71% above the recent low of -69.96.
The current earnings forecast score of Emergent BioSolutions Inc is 8.00. The average price target is 11.00, with a high of 12.00 and a low of 10.00.
The current price momentum score of Emergent BioSolutions Inc is 6.94. Currently, the stock price is trading between the resistance level at 7.65 and the support level at 5.35, making it suitable for range-bound swing trading.
The current institutional shareholding score of Emergent BioSolutions Inc is 7.00. The latest institutional shareholding proportion is 81.98%, representing a quarter-over-quarter decrease of 1.39%. The largest institutional shareholder is James Simons, holding a total of 683.25K shares, representing 0.01% of shares outstanding, with 41.01% increase in holdings.
The current risk assessment score of Emergent BioSolutions Inc is 4.64. The company's beta value is 2.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.